Shares of Hims & Hers Health Inc. (HIMS) experienced a significant downturn during Friday's trading session, plummeting 5.08% as investors reacted to news of a groundbreaking deal between the White House and major pharmaceutical companies for weight-loss drugs.

The telehealth company's stock decline comes in the wake of an announcement that President Donald Trump, along with pharmaceutical giants Eli Lilly and Novo Nordisk, have reached an agreement to substantially reduce the prices of popular GLP-1 weight-loss drugs for government healthcare programs and cash-paying customers. This move aims to expand access to these medications by bringing prices down to an average range of $149 to $350 per month for Americans.

The deal's potential to increase accessibility to weight-loss medications through traditional pharmaceutical channels could pose a significant threat to Hims & Hers Health's business model, which relies on telehealth consultations and prescriptions. As the market digests the implications of this agreement, investors appear to be reevaluating the company's growth prospects in the competitive weight-loss sector, leading to today's sharp stock decline.